China Pharma Holdings (CPHI) Receivables (2010 - 2026)
China Pharma Holdings (CPHI) posted Receivables of $257919.0 for Q1 2026, down 15.07% on a QoQ basis from $303696.0 in Q4 2025, and down 29.9% year-over-year from $367947.0 in Q1 2025.
China Pharma Holdings (CPHI) Receivables (2010 - 2026) Analysis & Trends
China Pharma Holdings' Receivables history runs 17 years deep, the most recent figure standing at $257919.0 for Q1 2026.
- Quarterly Receivables fell 29.9% year-over-year to $257919.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $257919.0 (down 29.9% YoY) and the FY2025 annual result came in at $303696.0, down 97.81% from the prior year.
- Receivables was $257919.0 for Q1 2026 at China Pharma Holdings, down from $303696.0 in the prior quarter.
- Across five years, Receivables topped out at $14.4 million in Q4 2023 and bottomed at $91753.0 in Q2 2023.
- A 5-year average of $4.5 million and a median of $450670.0 in 2022 frame the typical range for Receivables.
- Annual changes were most pronounced in 2024 — Receivables soared 13093.89% — and 2025, when it slumped 98.0%.
- China Pharma Holdings' Receivables stood at $450670.0 in 2022, then soared by 3106.0% to $14.4 million in 2023, then retreated by 4.14% to $13.8 million in 2024, then tumbled by 97.81% to $303696.0 in 2025, then dropped by 15.07% to $257919.0 in 2026.
- Business Quant data shows CPHI's Receivables at $257919.0 in Q1 2026, $303696.0 in Q4 2025, and $285913.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 257,919.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 257,919.00 |
| Dec 31, 2025 | 303,696.00 |
| Sep 30, 2025 | 285,913.00 |
| Jun 30, 2025 | 13.96 Mn |
| Mar 31, 2025 | 367,947.00 |
| Dec 31, 2024 | 13.85 Mn |
| Sep 30, 2024 | 14.32 Mn |
| Jun 30, 2024 | 283,510.00 |
| Mar 31, 2024 | 14.15 Mn |
| Dec 31, 2023 | 14.45 Mn |
| Sep 30, 2023 | 397,156.00 |
| Jun 30, 2023 | 91,753.00 |
| Mar 31, 2023 | 107,254.00 |
| Dec 31, 2022 | 450,670.00 |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 1.20 Mn |
| Mar 31, 2022 | 1.24 Mn |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 1.75 Mn |
| Jun 30, 2021 | 1.53 Mn |